Evidence map›Paper›PMID 32772223›Full record

ReviewMolecular neurobiology2020

Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases.

Giovanni Palermo, Sonia Mazzucchi, Alessandra Della Vecchia, Gabriele Siciliano, Ubaldo Bonuccelli, Carole Azuar, Roberto Ceravolo, Simone Lista, Harald Hampel, Filippo Baldacci

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Systematic Review with Meta-Analysis of Biofluid Markers for Huntington's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giovanni PalermoUnit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sonia MazzucchiUnit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alessandra Della VecchiaUnit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Gabriele SicilianoUnit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Ubaldo BonuccelliUnit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Carole AzuarCentre National de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.
Roberto CeravoloUnit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Simone ListaSorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, F-75013, Paris, France.
Harald HampelSorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, F-75013, Paris, France.
Filippo BaldacciUnit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. filippo.baldacci@unipi.it.ORCID http://orcid.org/0000-0002-8752-0556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most pressing challenges in the clinical research of neurodegenerative diseases (NDDs) is the validation and standardization of pathophysiological biomarkers for different contexts of use (CoUs), such as early detection, diagnosis, prognosis, and prediction of treatment response. Neurofilament light chain (NFL) concentration is a particularly promising candidate, an indicator of axonal degeneration, which can be analyzed in peripheral blood with advanced ultrasensitive methods. Serum/plasma NFL concentration is closely correlated with cerebrospinal fluid NFL and directly reflects neurodegeneration within the central nervous system. Here, we provide an update on the feasible CoU of blood NFL in NDDs and translate recent findings to potentially valuable clinical practice applications. As NFL is not a disease-specific biomarker, however, blood NFL is an easily accessible biomarker with promising different clinical applications for several NDDs: (1) early detection and diagnosis (i.e., amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, atypical parkinsonisms, sporadic late-onset ataxias), (2) prognosis (Huntington's disease and Parkinson's disease), and (3) prediction of time to symptom onset (presymptomatic mutation carriers in genetic Alzheimer's disease and spinocerebellar ataxia type 3).

Indexed as

AnimalsBiomarkersHumansMass ScreeningNeurodegenerative DiseasesNeurofilament ProteinsPrognosisRisk FactorsBiomarkersneurofilament protein LNeurofilament ProteinsAlzheimer’s diseaseAmyotrophic lateral sclerosisBiomarkersCreutzfeldt–Jakob diseaseNFLParkinsonian syndromes

Identifiers

PMID32772223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.